Fig. 3From: Long-term evaluation of the seroprevalence of SARS-CoV-2 IgG and IgM antibodies in recovered patients: a meta-analysisSubgroup analysis for follow-up time (A), country (B), sample size (C) estimating the IgG antibodies seroprevalences of recovered COVID-19 patients in the long-term follow-up studies (follow-up time ≥ 6 months). Effect estimates are reported with 95% confidence intervals (CIs) and p-valuesBack to article page